



CPCRN
Cancer Prevention and
Control Research Network

Modeling Evidence-Based Interventions (EBI) Impact Workgroup Update

Stephanie B. Wheeler, PhD, MPH
Health Policy and Management
University of North Carolina at Chapel Hill



This presentation was supported by Cooperative Agreement Number U48 DP005006 from the Centers for Disease Control and Prevention. The findings and conclusions in this presentation are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



Stephanie Wheeler,
UNC

Our Team



Florence Tangka,
CDC



Mike Pignone,
UNC



Melinda Davis,
OHSU



Lisa Richardson,
CDC




Kristen Hassmiller
Lich, UNC



Stephanie Renfro,
OHSU



Maria Mayorga,
NC State



Justin Trogdon,
UNC



Jackie Shannon,
OHSU



Leah Frerichs,
UNC



Paul Shafer,
UNC



John McConnell,
OHSU



Sarah Drier,
UNC

Modeling EBI Impact Workgroup Objectives

- Inform cancer screening-focused EBI implementation planning, practice-level change, and policies at the state and national levels
- Use models to simulate and compare the impact of alternate “what if” scenarios on:
 - Cancer screening rates in a given year and over time
 - The percent of subpopulations up-to-date with routine screening, cancer incidence, cancer stage at diagnosis, cancer deaths and/or life-years lost due to cancer
 - Costs and cost-effectiveness of CRC screening-focused interventions
- Integrate best available evidence into decision support models to increase cancer screening overall and address observed disparities

Research Questions Examined Since May 2016


- Claims data only analyses:
 - 1) What is the regional variation in CRC screening within publically and commercially insured populations in OR?
 - 2) What is the regional variation in CRC screening modalities used across CCOs in OR?
- Simulation analyses:
 - 3) What is the projected impact of Medicaid expansion on CRC screening and outcomes among African American males in NC?
 - 4) *What is the impact of the ACA private insurance expansion on CRC screening and outcomes in NC?**
 - 5) *What is the impact of the ACA private insurance expansion and Medicaid expansion on CRC screening and outcomes in OR?**
 - 6) *What interventions are recommended to increase CRC screening in publically insured populations in OR?**

* in progress

What's Next for the Modeling EBI Workgroup

- What would it take to get to 80% by 2018 in NC? In OR?
- How can we best integrate decision support modeling with implementation science for CRC screening?
 - To inform implementation of specific CRC screening EBIs in geographically distinct areas and populations, e.g.:
 - Urban, publicly insured populations
 - FQHCs
 - CCOs in OR
 - Eastern NC
 - To develop best practices for using simulation in stakeholder implementation decision support

Model schematic



Census data (American Community Survey, Public Use Microdata Sample) and **RTI Synthetic population**

BRFSS (Behavioral Risk Factors Surveillance System)

Claims (Medicare, Medicaid, Commercial), **ARF** (Area Resource file), **State Medical Facilities Plan**

Lit Review & Stakeholder interviews

Cancer Registry

Synthetic population input files

Impact of ACA
Predictive multivariable logit model

Compliance Model
Predictive, multi-level logit model

Modality Model
Predictive, multi-level logit model

Natural History Model



CRC Simulation Model



Illustrative Model Outputs

Modules	Examples of Simulation outputs
 <p>Clinical or health policy Intervention scenarios</p>	<p>Costs, cost-effectiveness and other consequences of interventions or policies</p>
 <p>Healthy lifestyle</p>	<p>Prevalence of tobacco and alcohol use Percentage up-to-date with screening</p>
 <p>The population</p>	<p>Prevalence of benign tumors (e.g. adenomas) Average life expectancy Cancer mortality rates by race and ethnicity</p>
 <p>Healthcare infrastructure</p>	<p>Service volume by facility</p>
 <p>Cancer screening, diagnosis, treatment & surveillance</p>	<p>Percent up-to-date with screening Number of false positives Adherence rate of diagnostic testing</p>
 <p>Natural history of cancer</p>	<p>Cancer incidence Stage of cancer diagnoses Cancer mortality Cancer cases averted Life years gained.</p>

Progress

Research Questions Examined Since May 2016

- Claims data only analyses:
 - 1) What is the regional variation in CRC screening within publically and commercially insured populations in OR?
 - 2) What is the regional variation in CRC screening modalities used across CCOs in OR?
- Simulation analyses:
 - 3) What is the projected impact of Medicaid expansion on CRC screening and outcomes among African American males in NC?
 - 4) What is the impact of the ACA private insurance expansion on CRC screening and outcomes in NC?
 - 5) What is the impact of the ACA private insurance expansion and Medicaid expansion on CRC screening and outcomes in OR?
 - 6) What interventions are recommended to increase CRC screening in publically insured populations in OR?

Aim 1 Progress (CRC Screening Variation in Oregon - County)



Preventive Medicine

Available online 13 May 2017

In Press, Accepted Manuscript — Note to users



Geographic and population-level disparities in colorectal cancer testing: A multilevel analysis of Medicaid and commercial claims data

Melinda M. Davis^{a, b}, Stephanie Renfro^c, Robyn Pham^b, Kristen Hassmiller Lich^d, Jackilen Shannon^e, Gloria D. Coronado^f, Stephanie B. Wheeler^{d, g, h}


[Show more](#)

<https://doi.org/10.1016/j.ypmed.2017.05.001>

[Get rights and content](#)

Highlights

- Despite insurance, 58% had not received colorectal cancer (CRC) testing.
- CRC testing varied from 22.4% to 46.8% across Oregon's 36 counties.
- Individual, community, and health system-level factors impacted CRC testing.
- Counties with higher socioeconomic deprivation displayed lower CRC testing.
- Work to increase CRC testing in targeted counties and populations is needed.




- Controlling for age, beneficiaries had greater odds of CRC testing if they were female (OR 1.04, 95% CI 1.01-1.08), compared to rural residents (OR 1.14, 95% CI 1.07-1.21).
- Accessing primary care (OR 2.47, 95% CI 2.37-2.57) and colonoscopy (OR 0.98, 95% CI 0.92-1.03) was associated with CRC testing.

Research Questions Examined Since May 2016

- Claims data only analyses:
 - 1) What is the regional variation in CRC screening within publically and commercially insured populations in OR?
 - 2) What is the regional variation in CRC screening modalities used across CCOs in OR?
- Simulation analyses:
 - 3) What is the projected impact of Medicaid expansion on CRC screening and outcomes among African American males in NC?
 - 4) What is the impact of the ACA private insurance expansion on CRC screening and outcomes in NC?
 - 5) What is the impact of the ACA private insurance expansion and Medicaid expansion on CRC screening and outcomes in OR?
 - 6) What interventions are recommended to increase CRC screening in publically insured populations in OR?

Aim 1 Progress (CRC Screening Variation in Oregon – Coordinated Care Organizations)

- RQ: How might Medicaid ACOs affect patterns of CRC screening and testing modalities used over time and across geographic regions?
 - **Participants:** Oregon Medicaid members between January 2010 and December 2014 who were age-eligible for CRC screening and met study inclusion criteria.
 - **Measures:** We examined incident (first evidence of) CRC screening and corresponding testing modality (i.e., colonoscopy, sigmoidoscopy, fecal testing) at the person level.





Research Questions Examined Since May 2016

- Claims data only analyses:
 - 1) What is the regional variation in CRC screening within publically and commercially insured populations in OR?
 - 2) What is the regional variation in CRC screening modalities used across CCOs in OR?
- Simulation analyses:
 - 3) What is the projected impact of Medicaid expansion on CRC screening and outcomes among African American males in NC?
 - 4) What is the impact of the ACA private insurance expansion on CRC screening and outcomes in NC?
 - 5) What is the impact of the ACA private insurance expansion and Medicaid expansion on CRC screening and outcomes in OR?
 - 6) What interventions are recommended to increase CRC screening in publically insured populations in OR?

Simulation Model Updates since May 2016

- Added racial specificity in underlying natural history of CRC
- Updated input parameters (compliance with surveillance etc.) based on evidence
- Included more realistic trajectories of colonoscopy screening
- Updated underlying synthetic population to 2010 Census
- Estimated impact of ACA on insurance coverage using BRFSS and Medicaid eligibility criteria, both NC and OR: initial effect in 2014 & Secondary effect 2014-2015
- Surveyed the evidence regarding costs of post-screening follow-up care
- Replacing NC with OR data and statistical models
- Recalibrated secular trend and self report adjustment (for NC) to match updated BRFSS







- **ACA and Medicaid Expansion begins to close disparity gap between African American and White males**
- **Without ACA, the disparity gap continues to widen**

Change in disparity gap between White and African American males in the percent up-to-date with colorectal cancer screening from baseline to 2023 by NC geographic regions


Control



Medicaid Expansion (High Enrollment and Compliance)



Differences in *cumulative CRC screening and treatment cost savings per person* between policy scenarios and the control scenario



ACA and Medicaid Expansion result in substantial long-term cost savings, especially for African American males

Research Questions Examined Since May 2016

- Claims data only analyses:
 - 1) What is the regional variation in CRC screening within publically and commercially insured populations in OR?
 - 2) What is the regional variation in CRC screening modalities used across CCOs in OR?
- Simulation analyses:
 - 3) What is the projected impact of Medicaid expansion on CRC screening and outcomes among African American males in NC?
 - 4) What is the impact of the ACA private insurance expansion on CRC screening and outcomes in NC?
 - 5) What is the impact of the ACA private insurance expansion and Medicaid expansion on CRC screening and outcomes in OR?
 - 6) What interventions are recommended to increase CRC screening in publically insured populations in OR?

Expanding Coverage is Not Enough: Estimating the Impact of ACA/Medicaid Expansion

- Insurance uptake mechanisms
 - Medicaid
 - Newly eligible
 - “Woodwork” enrollees
 - Insurance Exchanges/Marketplace
 - Newly enrolled through self-pay
 - Previously eligible for employer-sponsored coverage but unenrolled
 - Predicted uptake modeled using 2013-2015 BRFSS by age group, gender, race/ethnicity, income, and marital status

Simulating the impact of insurance expansion on CRC outcomes in NC & OR

	North Carolina	Oregon
Status Quo	ACA w/o Medicaid expansion	ACA w/ Medicaid expansion
Pre-exchange insurance	No ACA No Medicaid expansion	No ACA No Medicaid expansion
Complete Repeal of ACA	Includes loss of insurance from the exchanges	Includes loss of insurance from the exchanges and Medicaid
AHCA	Based on CBO estimates of insurance loss	Based on CBO estimates of insurance loss
ACA + Medicaid expansion (on January 2018)	As operationalized in other states since 2014	—————
Universal insurance	Medicare for all	Medicare for all

Research Questions Examined Since May 2016

- Claims data only analyses:
 - 1) What is the regional variation in CRC screening within publically and commercially insured populations in OR?
 - 2) What is the regional variation in CRC screening modalities used across CCOs in OR?
- Simulation analyses:
 - 3) What is the projected impact of Medicaid expansion on CRC screening and outcomes among African American males in NC?
 - 4) What is the impact of the ACA private insurance expansion on CRC screening and outcomes in NC?
 - 5) What is the impact of the ACA private insurance expansion and Medicaid expansion on CRC screening and outcomes in OR?
 - 6) What interventions are recommended to increase CRC screening in publically insured populations in OR?

EBI Screening Intervention Scenarios for OR

- Existing (Simulated in NC)
 - Mailed reminders (no FIT kit)
 - Mass media campaigns
 - Vouchers for uninsured
 - Endoscopy expansion
- Novel (Planned for OR)
 - Direct Mail of FIT (potential variations, see Table)
 - Outreach (navigators, panel managers)
 - Practice Improvement?

ORIGINAL RESEARCH
Cost-Effectiveness Analysis of Four Simulated Colorectal Cancer Screening Interventions, North Carolina

Kristen Hassmiller Lich, PhD¹; David A. Cornejo²; Maria E. Mayorga, PhD²;
Michael Pignone, MD, MPH^{3,4,5,6}; Florence K.L. Tangka, PhD⁷;
Lisa C. Richardson, MD, MPH⁷; Tzy-Mey Kuo, PhD, MPH³; Anne-Marie Meyer, PhD^{3,8};
Ingrid J. Hall, PhD, MPH⁷; Judith Lee Smith, PhD⁷; Todd A. Durham, MS⁴;
Steven A. Chall, MS⁹; Trisha M. Crutchfield, MHA, MSIS^{4,6};
Stephanie B. Wheeler, PhD, MPH^{1,3,4}

Table. Mailed stool test variations – assumes that return postage is included


Source	Test Characteristics	Patient Characteristics	Follow-up Intensity (and who delivered)	Patient Incentive(s)
Clinic	Type/sensitivity (FIT vs FOBT)	Screening history (yes, no)	None	None
Health Plan	Samples required (one, two, three)	Ethnicity (Hispanic, Non-Hispanic)	Reminders: Auto, live, text	\$25
Combo		Insurance Type (Medicaid, Commercial)	Reminders + Navigator follow-up	\$50
		Geographic location		

What's Next?


What's Next for the Modeling EBI Workgroup

- What would it take to get to 80% by 2018 in NC? In OR?
- How can we best integrate decision support modeling with implementation science with a focus on CRC screening?
 - To inform implementation of specific CRC screening EBIs in geographically distinct areas and populations, e.g.:
 - Urban, publicly insured populations
 - FQHCs
 - CCOs in OR
 - Eastern NC
 - To develop best practices for using simulation in stakeholder decision support

OR CCO A





OR CCO B



OREGON STATEWIDE
INTERCOMMUNITY HEALTH NETWORK

Modality

- Any CRC Screening
- Colonoscopy
- Flexible Sigmoidoscopy
- Fecal Testing



CCO A

People are moving in and out of being "up-to-date"





CCO B

Practice and policy are changing, constantly...



DYNAMICS!!!

People are moving in and out of CCOs (and Medicaid)...



Behaviors are influenced by environment and systems...





CCO A

CCO B

What interventions should CCO A invest in? CCO B?

How do we know which evidence-based strategies to even consider?



What regional capacity would be needed to get both up to screening targets?

Finalizing intervention plans in the face of uncertainty

Recommendation based on most Cost Effective Life Years UTD

Mass Media Cost 3,000,000
 Mailed Reminder Cost 1,679,578
 WTP 10

Max Total Cos Yrs UTD	Yrs UTD	Max Total Cos	Mailed Reminder																														
			Effect	0.2	0.3	0.4	0.5	0.6	0.7	0.8	0.9	1	1.1	1.2	1.3	1.4	1.5	1.6	1.7	1.8	1.9	2	2.1	2.2	2.3	2.4	2.5	2.6	2.7	2.8	2.9	3	
\$54,350	5,435		0.2	N	N	N	N	N	N	N	N	N	N	N	N	N	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	
\$125,050	12,505		0.3	N	N	N	N	N	N	N	N	N	N	N	N	N	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	
\$221,050	22,105		0.4	N	N	N	N	N	N	N	N	N	N	N	N	N	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	
\$350,370	35,037		0.5	N	N	N	N	N	N	N	N	N	N	N	N	N	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	
\$507,620	50,762		0.6	N	N	N	N	N	N	N	N	N	N	N	N	N	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	
\$689,530	68,953		0.7	N	N	N	N	N	N	N	N	N	N	N	N	N	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	
\$901,850	90,185		0.8	N	N	N	N	N	N	N	N	N	N	N	N	N	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	
\$1,136,140	113,614		0.9	N	N	N	N	N	N	N	N	N	N	N	N	N	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	
\$1,398,600	139,860		1	N	N	N	N	N	N	N	N	N	N	N	N	N	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	
\$1,694,950	169,495		1.1	N	N	N	N	N	N	N	N	N	N	N	N	N	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	
\$2,024,030	202,403		1.2	N	N	N	N	N	N	N	N	N	N	N	N	N	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	
\$2,331,030	233,103		1.3	N	N	N	N	N	N	N	N	N	N	N	N	N	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	
\$2,606,950	260,695		1.4	N	N	N	N	N	N	N	N	N	N	N	N	N	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	
\$2,899,460	289,946		1.5	N	N	N	N	N	N	N	N	N	N	N	N	N	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	
\$3,210,460	321,046		1.6	MM	MM	MM	MM	MM	MM	MM	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR								
\$3,513,470	351,347		1.7	MM	MM	MM	MM	MM	MM	MM	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR								
\$3,848,570	384,857		1.8	MM	MM	MM	MM	MM	MM	MM	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR								
\$4,200,280	420,028		1.9	MM	MM	MM	MM	MM	MM	MM	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR								
\$4,554,260	455,426		2	MM	MM	MM	MM	MM	MM	MM	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR								
\$4,931,800	493,180		2.1	MM	MM	MM	MM	MM	MM	MM	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR								
\$5,324,040	532,404		2.2	MM	MM	MM	MM	MM	MM	MM	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR								
\$5,733,080	573,308		2.3	MM	MM	MM	MM	MM	MM	MM	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR								
\$6,155,260	615,526		2.4	MM	MM	MM	MM	MM	MM	MM	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR								
\$6,581,640	658,164		2.5	MM	MM	MM	MM	MM	MM	MM	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR								
\$6,842,500	684,250		2.6	MM	MM	MM	MM	MM	MM	MM	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR								
\$7,094,760	709,476		2.7	MM	MM	MM	MM	MM	MM	MM	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR								
\$7,348,660	734,866		2.8	MM	MM	MM	MM	MM	MM	MM	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR								
\$7,599,340	759,934		2.9	MM	MM	MM	MM	MM	MM	MM	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR								
\$7,842,640	784,264		3	MM	MM	MM	MM	MM	MM	MM	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR								



Acknowledgments

- CDC SIP 14-011 Cancer Prevention and Control Research Network (CPCRN) (PI: Wheeler)
- CDC SIP 11-041 “Behavioral economics of colorectal cancer screening in underserved populations” (Co-PIs: Pignone and Wheeler)
- AHRQ 1-K-12 HS019456-01 Mentored Clinical Scientists Comparative Effectiveness Development Award (PI: Guise; Scholar: Davis)
- AHRQ 1-K-12 HS019468-01 Mentored Clinical Scientists Comparative Effectiveness Development Award (PI: Weinberger; Scholar: Wheeler)
- NIH K05 CA129166 Established Investigator Award in Cancer Prevention and Control: Improving Cancer-Related Patient Decision Making (PI: Pignone)
- NC Translational and Clinical Sciences Institute Pilot Grant “Using systems science methods to improve colorectal cancer screening in North Carolina” (PI: Lich)
- CMMI-1150732 CAREER: Incorporating Patient Heterogeneity and Choice into Predictive Models of Health and Economic Outcomes”. National Science Foundation (PI: Mayorga)
- University of North Carolina at Chapel Hill Cancer Research Fund

Oregon vs. North Carolina

	Oregon	North Carolina
Population, 2014	3,970,239	9,943,964
Persons 65 years and over, 2013	15.5%	14.3%
Females	50.5%	51.3%
Race/Ethnicity (selected), 2013		
White alone	88.1%	71.7%
Black or African American alone	2.0%	22.0%
Hispanic or Latino	12.3%	8.9%
Persons below poverty level, 2009-2013	16.2%	17.5%
Land area in square miles, 2010	95,988	48,618
Persons per square mile, 2010	39.9	196.1

Source: <http://quickfacts.census.gov/qfd/index.html>